We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+9.15%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$196M
AUM Growth
+$19.4M
(+11%)
Cap. Flow
+$8.89M
Cap. Flow
% of AUM
4.54%
Top 10 Holdings %
Top 10 Hldgs %
46.87%
Holding
69
New
3
Increased
33
Reduced
3
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TEAR
TearLab Corporation
TEAR
|
+$4.8M |
| 2 |
Insmed
INSM
|
+$3.7M |
| 3 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$1.94M |
| 4 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$1.86M |
| 5 |
Verastem
VSTM
|
+$1.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanda Pharmaceuticals
VNDA
|
+$3.29M |
| 2 |
SPNC
Spectranetics Corp
SPNC
|
+$2.88M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
+$2.52M |
| 4 |
Align Technology
ALGN
|
+$2.05M |
| 5 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.63% |
| 2 | Consumer Staples | 0.8% |
| 3 | Financials | 0.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
AtriCure
ATRC
$1.92B
| $14.5M | 7.38% |
705,570
+69,400
| +11% | +$1.34M |
|
2
NeoGenomics
NEO
$1.96B
| $13.8M | 7.06% |
2,962,024
+278,934
| +10% | +$1.21M |
|
|
AKRX
3
DELISTED
Akorn Inc
AKRX
| $12.1M | 6.2% |
255,711
+23,019
| +10% | +$1.05M |
|
4
Harvard Bioscience
HBIO
$27.5M
| $9.09M | 4.64% |
156,250
+14,978
| +11% | +$805K |
|
|
SPNC
5
DELISTED
Spectranetics Corp
SPNC
| $7.91M | 4.04% |
227,617
-84,641
| -27% | -$2.88M |
|
|
SRGA
6
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $7.72M | 3.94% |
52,089
+4,962
| +11% | +$756K |
|
|
NXTM
7
DELISTED
NxStage Medical Inc.
NXTM
| $7.12M | 3.64% |
411,717
+38,553
| +10% | +$681K |
|
8
Ligand Pharmaceuticals
LGND
$5.76B
| $7.05M | 3.6% |
146,489
+15,120
| +12% | +$579K |
|
|
TLGT
9
DELISTED
Teligent, Inc
TLGT
| $6.58M | 3.36% |
80,626
+7,180
| +10% | +$693K |
|
|
TEAR
10
DELISTED
TearLab Corporation
TEAR
| $5.87M | 3% |
295,048
+199,727
| +210% | +$4.8M |
|
|
OXFD
11
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $5.78M | 2.95% |
410,150
+136,677
| +50% | +$1.86M |
|
|
ARRY
12
DELISTED
Array Biopharma Inc
ARRY
| $5.72M | 2.92% |
775,726
-353,834
| -31% | -$2.52M |
|
|
ELGX
13
DELISTED
Endologix Inc
ELGX
| $4.73M | 2.42% |
27,726
+2,689
| +11% | +$407K |
|
14
Celldex Therapeutics
CLDX
$2.99B
| $4.71M | 2.41% |
11,276
+1,035
| +10% | +$370K |
|
15
Omnicell
OMCL
$1.61B
| $4.7M | 2.4% |
133,858
+13,373
| +11% | +$441K |
|
|
16
Insmed
INSM
$21.4B
| $4.37M | 2.23% |
+210,066
| New | +$3.7M |
|
17
Bio-Techne
TECH
$11.2B
| $4.32M | 2.2% |
172,144
+15,172
| +10% | +$361K |
|
18
QuidelOrtho
QDEL
$1.14B
| $4.25M | 2.17% |
157,665
+14,573
| +10% | +$372K |
|
|
NVDQ
19
DELISTED
Novadaq Technologies Inc.
NVDQ
| $3.97M | 2.03% |
244,238
+21,339
| +10% | +$317K |
|
|
ENZ
20
DELISTED
Enzo Biochem, Inc.
ENZ
| $3.91M | 2% |
1,324,322
+110,421
| +9% | +$361K |
|
21
AngioDynamics
ANGO
$611M
| $3.84M | 1.96% |
215,783
+21,271
| +11% | +$395K |
|
22
Standard BioTools
LAB
$340M
| $3.77M | 1.92% |
89,492
+8,879
| +11% | +$351K |
|
|
STRM
23
DELISTED
Streamline Health Solutions
STRM
| $3.54M | 1.81% |
66,416
+6,167
| +10% | +$372K |
|
|
LCI
24
DELISTED
Lannett Company, Inc.
LCI
| $3.37M | 1.72% |
12,442
+1,001
| +9% | +$227K |
|
25
Veracyte
VCYT
$3.7B
| $3.2M | 1.64% |
440,003
+46,077
| +12% | +$377K |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q1 2015 Portfolio in Review
As of Q1 2015, First Light Asset Management held 69 positions worth $196M, up 11% from $176M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
First Light Asset Management deployed $8.89M of net new capital in Q1 2015, opening 3 new positions and adding to 33 existing holdings. Its largest new stake was Insmed: 210,066 shares worth $4.37M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Consumer Staples and Financials.
On the sell side, the largest reduction was Spectranetics Corp, an estimated $2.88M trimmed.
- First Light Asset Management's largest Q1 2015 buy was Insmed: 210,066 shares worth $4.37M.
- First Light Asset Management added most to TearLab Corporation in Q1 2015, an estimated $4.8M increase.
- First Light Asset Management's biggest Q1 2015 reduction was Spectranetics Corp, cutting an estimated $2.88M.
- First Light Asset Management fully exited Vanda Pharmaceuticals in Q1 2015, selling an estimated $3.29M.
- First Light Asset Management's ten largest holdings make up 47% of its $196M portfolio in Q1 2015.
- First Light Asset Management opened 3 new positions and closed 7 in Q1 2015.
- First Light Asset Management's portfolio value rose 11% quarter-over-quarter to $196M.
Based on First Light Asset Management's 13F filing for Q1 2015, filed 15 May 2015.